Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

114.23 +3.73 (+3.38%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)... 
Via Benzinga
Exposures Product Safety
Pinterest To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
EMBARKNG On A New Label? New Sarepta DMD Data Leads To Old Debates
Sarepta released their Phase III EMBARK data that is actually consistent with my previous analysis that the drug likely works in younger patients but not older. 
Via Talk Markets
Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene Therapy
The drug didn't meet its primary goal in the pivotal study, but it met secondary measures. 
Via Investor's Business Daily
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
5 Analysts Have This to Say About Sarepta Therapeutics
Via Benzinga
Is Sarepta Therapeutics Stock a Top Growth Vehicle?
An upcoming data readout could fuel another rally in the biotech's shares. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Gene Editing Stocks to Generate Super-Charged Gains
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Sarepta Therapeutics Stock Showing Rising Relative Strength
Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Top Growth Stocks to Buy With $500
No need to break the bank to invest in stocks. 
Via The Motley Fool
Insiders Are Buying These 2 Stocks
Insider buying in both Loews (NYSE: L) and Sarepta (NASDAQ: SRPT) suggests a positive outlook for these stocks, potentially influencing investor sentiment. 
Via MarketBeat
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
Helping save and improve patients' lives in novel ways can be a lucrative activity. 
Via The Motley Fool
Over $25M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mostly higher on Monday, there were a few notable insider trades. 
Via Benzinga
$3M Bet On Tidewater? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.